“P selectin inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in P selectin inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
P selectin inhibitors Understanding
P selectin inhibitors: Overview P-Selectin (CD62P), previously termed PADGEM or GMP-140, is a single chain glycoprotein of 140 kDa expressed in platelets and endothelial cells. In platelets, P-selectin is stored in ? granules, whereas in endothelial cells it is found in Weibel–Palade bodies. P-selectin mediates the rolling of blood cells on the surface of the endothelium and initiates the attachment of leukocytes circulating in the blood to platelets, endothelial cells, and other leukocytes at sites of tissue injury and inflammation. P-selectin plays a key role in diseases associated with injury and arterial thrombosis. Increased expression of P-selectin is observed in coronary artery disease, acute myocardial infarction, stroke, and peripheral artery diseases. Increased level of sP-selectin and elevated P-selectin expression may be good markers of some types of carcinoma, such as neoplastic pulmonary diseases, breast, renal, and colon cancer, and blood cancer. P-selectin inhibition with protein therapeutics such as antibodies or soluble ligands given intravenously can decrease thrombosis in a mouse ligation model of venous thrombosis. Inhibition of P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) play a key role in proliferation of Multiple myeloma.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence P selectin inhibitors R&D. The therapies under development are focused on novel approaches for P selectin inhibitors.
P selectin inhibitors Emerging Drugs Chapters This segment of the P selectin inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
P selectin inhibitors Emerging Drugs
• DSTAT: Chimerix
DSTAT (dociparstat sodium) is an intravenous formulation of chemically modified heparin with very low anticoagulant activity. DSTAT targets key protein pathways important for AML blast cell migration to the bone marrow and retention of these cells in the marrow where they are protected from chemotherapy. DSTAT (CX-01) also binds with proteins involved in chemotherapy resistance and the delay in platelet recovery after chemotherapy. DSTAT is in Phase III clinical trial studies for the treatment of AML. DSTAT has received Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration for the treatment of AML. In July 2019, Chimerix announced the completion of an exclusive worldwide license of DSTAT from Cantex Pharmaceuticals.
• Inclacumab: Global Blood Therapeutics
Inclacumab is a novel, fully human monoclonal antibody designed to inhibit P-selectin. It is in development for SCD patients with frequent pain crises, also known as vaso-occlusive crises (VOCs). P-selectin inhibition is clinically validated to reduce VOCs, a complication of SCD. We have an exclusive worldwide licensing agreement with Roche for inclacumab. In July 2018, Global Blood Therapeutics received exclusive worldwide rights, and sublicensing rights, to develop, manufacture, and commercialize Roche’s Inclacumab.
Further product details are provided in the report……..
P selectin inhibitors: Therapeutic Assessment This segment of the report provides insights about the different P selectin inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on P selectin inhibitors
There are approx. 8+ key companies which are developing the P selectin inhibitors. The companies which have their P selectin inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Chimerix.
This report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
P selectin inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
P selectin inhibitors: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses P selectin inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging P selectin inhibitors drugs.
P selectin inhibitors Report Insights • P selectin inhibitors Pipeline Analysis
• Therapeutic Assessment • Unmet Needs
• Impact of Drugs
P selectin inhibitors Report Assessment • Pipeline Product Profiles
Current Scenario and Emerging Therapies: • How many companies are developing P selectin inhibitors drugs?
• How many P selectin inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for P selectin inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the P selectin inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for P selectin inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players • Chimerix
• Modus Therapeutics
• Global Blood Therapeutics
• Suzhou Ronnsi Pharma
Osteosarcoma (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Drugs In Development, 2021, provides an overview of the Osteosarcoma (Oncology) pipeline landscape. Osteosarcoma is the most common cancer of the bone...
Adult Malignant Glioma Therapeutics market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Adult Malignant Glioma Therapeutics Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Adult Malignant Glioma Therapeutics...
Uterine Cancer Therapeutics & Diagnostics market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Uterine Cancer Therapeutics & Diagnostics Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Uterine Cancer Therapeutics...
Report Scope: This report examines the current and forecasted market potential of radiopharmaceuticals and therapeutics.It offers a detailed analysis of the technological advancement, competitive environment, market background, drivers and restraints, and market growth trends. The research report also includes market...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc., Quest Diagnostics, Thermo Fisher Scientific Inc., Pfizer, Bristol-Myers Squibb, Merck & Co. Inc., Tepnel Pharma Services, Abbott Laboratories, Takeda Pharmaceutical Company Ltd., and Eli Lilly and Company. The global precision medicine...
Executive Summary The Global Peptide Therapeutics Market is valued at USD 32.1 Billion in the year 2020. The growth of Peptide Therapeutics is directly associated with drug development. New drug discovery and product launch in chronic metabolic disorders would provide fruitful opportunities for Peptide Therapeutics Market....
Anti-tuberculosis Therapeutics market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Anti-tuberculosis Therapeutics Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Anti-tuberculosis Therapeutics types,...
Dermatological Therapeutics market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Dermatological Therapeutics Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Dermatological Therapeutics types, applications....
Sepsis Therapeutics market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Sepsis Therapeutics Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Sepsis Therapeutics types, applications. Further, Sepsis Therapeutics...
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drugs in Development, 2021 Summary Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.